The company sold 9.1 million shares of its common stock and warrants to purchase up to 9.1 million more shares at a combined offering price of $1.10 per share.
The company is offering 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million additional shares.
The University of Minnesota's Shilpa Gupta will work with Biocept on a study aimed at providing clinical support for the use of the firm's PD-L1 and AR tests.
Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.
Testing will be performed by Biocept in the US, and HarlePhil Ventures will sell, market, distribute, and collect reimbursements in the Philippines.
The firm's second quarter revenues grew more than seven times year over year based on a large increase in billable samples.
The firm's total revenues increased 47 percent to $221,369 for the quarter, mainly driven by continued expansion of commercial liquid biopsy test volumes.
The company said that it intends to use the proceeds of the stock and warrant offering for working capital, as well as general corporate purposes.
Biocept hopes data from the study will support the clinical utility of its liquid biopsy test to detect drug resistance mutations in NSCLC.
Quest Diagnostics will offer the Target Selector lung cancer mutation detection test in that country through a reference agreement with Biocept.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.